- Home
- IMCR vs VISN Comparison
IMCR vs VISN Comparison
Compare IMCR & VISN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | VISN |
|---|---|---|
| Founded | 2008 | 1976 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2016 | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMCR | VISN |
|---|---|---|
| Price | $29.87 | $4.27 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 4 |
| Target Price | ★ $59.40 | $5.67 |
| AVG Volume (30 Days) | 524.6K | ★ 7.1M |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 412.50% |
| EPS Growth | 30.39 | ★ 641.01 |
| EPS | N/A | ★ 29.48 |
| Revenue | $249,428,000.00 | ★ $1,931,600,000.00 |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | $10.23 | N/A |
| P/E Ratio | ★ N/A | $0.14 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.50 | $3.90 |
| 52 Week High | $40.71 | $19.91 |
Technical Indicators
Market Signals| Indicator | IMCR | VISN |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 24.39 |
| Support Level | $27.91 | N/A |
| Resistance Level | $31.11 | $6.76 |
| Average True Range (ATR) | 1.50 | 0.25 |
| MACD | 0.04 | -0.22 |
| Stochastic Oscillator | 39.13 | 10.44 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VISN Vistance Networks Inc. Common Stock
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.